OBJECTIVES: We sought to identify demographic and clinical features that were associated with expression of symptoms in the presence of Alzheimer disease (AD) neuropathologic changes. METHODS: We studied 82 asymptomatic (Clinical Dementia Rating global score = 0) and 824 symptomatic subjects (Clinical Dementia Rating score >0) with low to high AD neuropathologic changes at autopsy who were assessed at 1 of 34 National Institute on Aging-funded Alzheimer's Disease Centers. All subjects underwent a clinical examination within 1 year of death. Logistic regression was used to evaluate factors associated with the odds of being asymptomatic vs symptomatic. RESULTS: Asymptomatic subjects tended to have low neurofibrillary tangle scores but a wide range of neuritic plaque frequencies. There were, however, a few asymptomatic subjects with very high tangle and neuritic plaque burden, as well as symptomatic subjects with few changes. In the multivariable model, asymptomatic subjects were older (odds ratio [OR] = 1.04; 95% confidence interval [CI] = 1.01-1.07), had lower clinical Hachinski Ischemic Score (OR = 0.82; 95% CI = 0.69-0.97), were less likely to have an APOE ε4 allele (OR = 0.36; 95% CI = 0.16-0.83), and had lower neurofibrillary tangle score (OR = 0.28; 95% CI = 0.17-0.45) compared with symptomatic subjects. CONCLUSIONS: Dissociating clinical symptoms from pathologic findings better allows for investigation of preclinical AD. Our results suggest that although the severity of the pathology, particularly neurofibrillary tangles, has a large role in determining the extent of symptoms, other factors, including age, APOE status, and comorbidities such as cerebrovascular disease also explain differences in clinical presentation.
OBJECTIVES: We sought to identify demographic and clinical features that were associated with expression of symptoms in the presence of Alzheimer disease (AD) neuropathologic changes. METHODS: We studied 82 asymptomatic (Clinical Dementia Rating global score = 0) and 824 symptomatic subjects (Clinical Dementia Rating score >0) with low to high AD neuropathologic changes at autopsy who were assessed at 1 of 34 National Institute on Aging-funded Alzheimer's Disease Centers. All subjects underwent a clinical examination within 1 year of death. Logistic regression was used to evaluate factors associated with the odds of being asymptomatic vs symptomatic. RESULTS: Asymptomatic subjects tended to have low neurofibrillary tangle scores but a wide range of neuritic plaque frequencies. There were, however, a few asymptomatic subjects with very high tangle and neuritic plaque burden, as well as symptomatic subjects with few changes. In the multivariable model, asymptomatic subjects were older (odds ratio [OR] = 1.04; 95% confidence interval [CI] = 1.01-1.07), had lower clinical Hachinski Ischemic Score (OR = 0.82; 95% CI = 0.69-0.97), were less likely to have an APOE ε4 allele (OR = 0.36; 95% CI = 0.16-0.83), and had lower neurofibrillary tangle score (OR = 0.28; 95% CI = 0.17-0.45) compared with symptomatic subjects. CONCLUSIONS: Dissociating clinical symptoms from pathologic findings better allows for investigation of preclinical AD. Our results suggest that although the severity of the pathology, particularly neurofibrillary tangles, has a large role in determining the extent of symptoms, other factors, including age, APOE status, and comorbidities such as cerebrovascular disease also explain differences in clinical presentation.
Authors: Robert C Green; L Adrienne Cupples; Alex Kurz; Sanford Auerbach; Rodney Go; Dessa Sadovnick; Ranjan Duara; Walter A Kukull; Helena Chui; Timi Edeki; Patrick A Griffith; Robert P Friedland; David Bachman; Lindsay Farrer Journal: Arch Neurol Date: 2003-05
Authors: S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg Journal: Neurology Date: 1991-04 Impact factor: 9.910
Authors: S Duke Han; Jonathan Gruhl; Laurel Beckett; Hiroko H Dodge; Nikki H Stricker; Sarah Farias; Dan Mungas Journal: Brain Imaging Behav Date: 2012-12 Impact factor: 3.978
Authors: Nupur Ghoshal; Francisco García-Sierra; Joanne Wuu; Sue Leurgans; David A Bennett; Robert W Berry; Lester I Binder Journal: Exp Neurol Date: 2002-10 Impact factor: 5.330
Authors: Robert S Wilson; L L Barnes; C F Mendes de Leon; N T Aggarwal; J S Schneider; J Bach; J Pilat; L A Beckett; S E Arnold; D A Evans; D A Bennett Journal: Neurology Date: 2002-08-13 Impact factor: 9.910
Authors: Jason Hassenstab; Sarah E Monsell; Charles Mock; Catherine M Roe; Nigel J Cairns; John C Morris; Walter Kukull Journal: J Neuropathol Exp Neurol Date: 2015-11 Impact factor: 3.685
Authors: Corinne E Fischer; Winnie Qian; Tom A Schweizer; Colleen P Millikin; Zahinoor Ismail; Eric E Smith; Lisa M Lix; Paul Shelton; David G Munoz Journal: J Alzheimers Dis Date: 2016 Impact factor: 4.472
Authors: Patrick J Brown; Joel R Sneed; Bret R Rutherford; D P Devanand; Steven P Roose Journal: Int J Geriatr Psychiatry Date: 2013-10-03 Impact factor: 3.485
Authors: Sarah E Monsell; Charles Mock; Jason Hassenstab; Catherine M Roe; Nigel J Cairns; John C Morris; Walter Kukull Journal: Neurology Date: 2014-06-20 Impact factor: 9.910